Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
NCT03566511 · Meredith Hawkins · PHASE2 · terminated · last registry update 2025-05-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Grant funding ended. NIDDK grant renewed without an MR aim. No plans to do future studies.” | – | Registry record, Meredith Hawkins |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KCNJ11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-22Results posted on the registry: Boehringer Ingelheim, BI 1569912 + Repaglinide (NCT06367153)
- 2026-04-14Phase 3 first posted: Eurofarma Laboratorios S.A., Minoxidil oral solution + Placebo oral solution (NCT07529977)
- 2026-02-27Phase 3 first posted: Triple Hair Inc, TH07 + TH07 (NCT07435012)
- 2025-12-12Results posted on the registry: Eli Lilly and Company, Imlunestrant + Repaglinide (NCT05444556)
- 2025-12-11Results posted on the registry: Eli Lilly and Company, Repaglinide + Selpercatinib (NCT05469113)
- 2025-12-10Phase 3 first posted: Sheikh Zayed Federal Postgraduate Medical Institute, Minoxidil 5 % Topical Spray + minoxidil (NCT07273799)
- 2025-12-02Results posted on the registry: Boehringer Ingelheim, zongertinib + midazolam (NCT06494761)
- 2025-09-11Results posted on the registry: Albert Einstein College of Medicine, Naloxone + Diazoxide (NCT03608163)
- 2025-09-11Also stopped (terminated): Albert Einstein College of Medicine, Naloxone + Diazoxide (NCT03608163)
- 2025-07-23Phase 3 first posted: Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd., 5% minoxidil foam + Placebo for 5% Minoxidil Foam (NCT07080931)
- 2025-05-16Also stopped (terminated): Meredith Hawkins, Diazoxide + Placebo (NCT01028846)
- 2025-04-11Phase 3 first posted: Samson Clinical Operations Pty Ltd, Minoxidil + Placebo (NCT06924632)
- 2025-03-17Results posted on the registry: Eli Lilly and Company, Repaglinide + Pirtobrutinib (NCT06165146)
- 2025-03-14Results posted on the registry: Meredith Hawkins, Diazoxide + Placebo (NCT01028846)
- 2025-02-27Results posted on the registry: SWOG Cancer Research Network, Isatuximab (NCT03499808)
- 2025-01-03Results posted on the registry: Vicore Pharma AB, Drug Drug Interaction (NCT05830799)
- 2024-11-22Results posted on the registry: Pfizer, Voxelotor + Bupropion (NCT05981365)
- 2024-10-15Also stopped (withdrawn): Applied Biology, Inc., Topical minoxidil 5% (NCT06484881)
- 2024-07-15Phase 3 first posted: Applied Biology, Inc., Topical minoxidil 5% + DA-002 (NCT06501924)
- 2024-07-03Phase 3 first posted: Applied Biology, Inc., Topical minoxidil 5% (NCT06484881)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision